Heller A R, Heger J, Gama de Abreu M, Müller M P
Department of Anaesthesia and Intensive Care Medicine, Department of Anesthesiology and Critical Care Medicine, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany,
Anaesthesist. 2015 Mar;64(3):190-6. doi: 10.1007/s00101-015-0005-y. Epub 2015 Mar 11.
Hypotensive states that require fast stabilisation of blood pressure can occur during anaesthesia. In 1963, the 20:1 mixture of cafedrine/theodrenaline (Akrinor) was introduced in Germany for use in anaesthesia and emergency medicine in the first-line management of hypotensive states. Though on the market for many years, few pharmacodynamic data are available on this combination net beta-mimetic agent.
This study aimed to examine the drug combination in real-life clinical practice and recorded time to 10 % mean arterial blood pressure (MAP) increase and heart rate. Furthermore, potential factors that influence drug effectiveness under anaesthesia were assessed.
Data were collected within a standardised anaesthesia protocol. A total of 353 consecutive patients (female/male = 149/204) who received cafedrine/theodrenaline after a drop in MAP ≥ 5% were included in the study. The time to 10 % increase in MAP, dosage of cafedrine/theodrenaline, volume loading, blood pressure and heart rate were monitored over time.
Patients were a mean (standard deviation) of 64.4 ± 15.1 years old with a baseline MAP of 82 ± 14 mmHg, which dropped to a mean of 63 ± 10 mmHg during anaesthesia without gender differences. Cafedrine/theodrenaline (1.27 ± 1.0 mg/kg; 64 ± 50 µg/kg) significantly increased MAP (p < 0.001) by 11 ± 16 mmHg within 5 min, reaching peak values within 17.4 ± 9.0 min. Heart rate was not affected in a clinically significant manner. Cafedrine/theodrenaline induced a 10% MAP increase after 7.2 ± 4.6 min (women) and after 8.6 ± 6.3 min (men) (p = 0.018). Independent of gender, the dose of cafedrine/theodrenaline required to achieve the observed MAP increase of 14 ± 16 mmHg at 15 min was significantly different in patients with heart failure [1.78 ± 1.67 mg/kg (cafedrine)/89.0 ± 83.5 µg/kg (theodrenaline)] compared with healthy patients [1.16 ± 0.77 mg/kg (cafedrine)/58.0 ± 38.5 µg/kg (theodrenaline)] (p = 0.005). Concomitant medication with beta-blocking agents significantly prolonged the time to 10 % MAP increase [9.0 ± 7.0 vs. 7.3 ± 4.3 min (p = 0.008)].
Cafedrine/theodrenaline quickly restores MAP during anaesthesia. Female gender is associated with higher effectiveness, while heart failure and beta-blocker administration lower the anti-hypotonic effect. Prospective studies in defined patient populations are warranted to further characterise the effect of cafedrine/theodrenaline.
麻醉期间可能会出现需要快速稳定血压的低血压状态。1963年,卡非君/茶丙喘宁(阿克里诺)20:1混合制剂在德国被引入,用于麻醉和急诊医学中低血压状态的一线管理。尽管该药物已上市多年,但关于这种复方β-拟交感神经药的药效学数据却很少。
本研究旨在考察该药物组合在实际临床实践中的应用情况,并记录平均动脉压(MAP)升高10%的时间及心率。此外,还评估了麻醉状态下影响药物疗效的潜在因素。
在标准化麻醉方案中收集数据。本研究共纳入353例MAP下降≥5%后接受卡非君/茶丙喘宁治疗的连续患者(女性/男性=149/204)。随时间监测MAP升高10%的时间、卡非君/茶丙喘宁的剂量、液体负荷、血压和心率。
患者的平均(标准差)年龄为64.4±15.1岁,基线MAP为82±14 mmHg,麻醉期间降至平均63±10 mmHg,无性别差异。卡非君/茶丙喘宁(1.27±1.0 mg/kg;64±50 μg/kg)在5分钟内使MAP显著升高(p<0.001)11±16 mmHg,在17.4±9.0分钟内达到峰值。心率未受到具有临床意义的影响。卡非君/茶丙喘宁在女性7.2±4.6分钟后和男性8.6±6.3分钟后使MAP升高10%(p=0.018)。无论性别如何,在15分钟时实现观察到的MAP升高14±16 mmHg所需的卡非君/茶丙喘宁剂量,与健康患者[1.16±0.77 mg/kg(卡非君)/58.0±38.5 μg/kg(茶丙喘宁)]相比,心力衰竭患者[1.78±1.67 mg/kg(卡非君)/89.0±83.5 μg/kg(茶丙喘宁)]有显著差异(p=0.005)。同时使用β受体阻滞剂显著延长了MAP升高10%的时间[9.0±7.0 vs. 7.3±4.3分钟(p=0.008)]。
卡非君/茶丙喘宁可在麻醉期间快速恢复MAP。女性性别与更高的疗效相关,而心力衰竭和使用β受体阻滞剂会降低抗低血压作用。有必要在特定患者群体中进行前瞻性研究,以进一步明确卡非君/茶丙喘宁的作用。